Multiplikator forward rega marang pendapatan: Cumberland Pharma (CPIX)
Raw material shortage risks and logistical disruptions are putting pressure on the business of Cumberland Pharmaceuticals (CPIX). The company's forward P/S clearly demonstrates these fluctuations, where the value of 3.50 corresponds to the current metric. The integration of Kristalose and Caldolor into hospital standards provides stability, while production capacities continue to operate without interruption during a scheduled upgrade of packaging lines.
CPIX (cumberlandpharma.com): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi bursa perusahaan:
- rincian valuasi buku bisnis:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Cumberland Pharmaceuticals|CPIX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Cumberland Pharmaceuticals Inc.|CPIX - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Cumberland Pharmaceuticals Inc.|CPIX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Cumberland Pharmaceuticals|Likuiditas cepet cumberlandpharma.com
- data bathi bisnis lan rasio investasi:
CPIX - Bathi perusahaan|Proyeksi bathi mangsa ngarep Cumberland Pharmaceuticals|CPIX - Pangali rega marang bathi|Prakiraan rega marang bathi Cumberland Pharmaceuticals|CPIX - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Cumberland Pharmaceuticals|CPIX - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham (EPS TTM) Cumberland Pharmaceuticals|CPIX - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan cumberlandpharma.com|CPIX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Cumberland Pharmaceuticals
- data dodolan lan asil:
Ringkesan analisis perusahaan:CPIX (Cumberland Pharma)
The stable cash flow from the hospital products of Cumberland Pharmaceuticals (CPIX) allows for an objective business valuation based on the ratio of market capitalization to expected sales. Analyzing the forward P/S metric, an investor sees a current value of 3.50, which helps determine the degree of the asset's undervaluation relative to its ability to generate revenue and service obligations over the long term.
Karo sapa Cumberland Pharmaceuticals saingan
Multiplikator Forward P/S HLN (Haleon PLC)|Multiplikator Forward P/S Kenvue Corp KVUE|Verona Pharma PLC - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep jyongbio.com|LGND: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan AMRX|Rasio rega marang prakiraan pendapatan Perrigo Company|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alvotech ALVO|Multiplikator Forward P/S LQDA|GLPG: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake MannKind Corp (MNKD)|AMPH: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TBPH|AQST (Aquestive Corp) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan scPharmaceuticals Inc. (SCPH)|Multiplikator forward rega marang pendapatan TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan SXT Pharmaceuticals SXTC|Rega forward marang dodolan EPRX|BHST - Rasio rega marang prakiraan pendapatan|eXoZymes (EXOZ) - Multiplikator forward rega marang pendapatan|ORMP: Multiplikator Forward P/S|ENTX: Rasio rega marang pendapatan sing dikarepake|HYFT (ipatherapeutics.com) - Multiplikator Forward P/S|Multiplikator Forward P/S ABVC BioPharma|Rasio rega marang prakiraan pendapatan Quantum BioPharma (QNTM)|FibroGen (FGEN) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S TELO (telomirpharma.com)|RANI - Multiplikator forward rega marang pendapatan|SNYR - Rasio rega marang prakiraan pendapatan|rallybio.com - Rasio rega marang pendapatan sing dikarepake|LEXX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pulmatrix Inc|PTHL (Pheton Holdings) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Aptorum Group Limited APM|Rasio rega marang prakiraan pendapatan Lyra Therapeutics (LYRA)|Multiplikator forward rega marang pendapatan Impact BioMedical Inc IBO|Rasio rega marang prakiraan pendapatan tnfpharma.com TNFA|Rega forward marang dodolan YCBD|PainReform Ltd - Multiplikator Forward P/S|Altamira Therapeutics Ltd (CYTO) - Multiplikator forward rega marang pendapatan|lipella.com (LIPO) - Rasio rega marang prakiraan pendapatan|OptiNose (OPTN) - Multiplikator Forward P/S|PIRS (Pieris Pharmaceuticals Inc) - Multiplikator Forward P/S|PROC: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|Multiplikator Forward P/S Qilian International Corp (QLI)|ACELYRIN, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S tffpharma.com TFFP
